The Sarcoma Coalition is committed to support sarcoma research through: Sarcoma member organizations posting research projects that encompass a variety of sarcoma subtypes where collaboration on the Sarcoma Coalition website Message Board to announce:
– Collaborative opportunities to promote sarcoma research initiatives
– Explore co-funding opportunities that may arise through the research community
– Post successful research collaborations on FB and provide alerts for the Sarcoma Coalition newsletters,
with follow-up research collaboration results also posted on the Message Board of the Sarcoma Coalition website.
Rare Disease Congressional Caucus – Please contact your Members of Congress and urge them to join the Rare Disease Congressional Caucus.
Sarcoma Cancer Foundation of Canada – RESEARCH INTO RARE FORM OF VASCULAR SARCOMA CANCER RECEIVES $1 MILLION IN FUNDING – July 5, 2022 –Sarcoma Cancer Foundation of Canada Celebrates Largest Ever Investment in Canadian EHE Sarcoma Cancer Research. TORONTO, ON, July 5, 2022 – The Sarcoma Cancer Foundation of Canada is pleased to announce a one-million-dollar investment into an exciting new research initiative that will evolve the collective baseline of Epithelioid Hemangioendothelioma (EHE), a rare vascular form of a sarcoma. This Canadian-led research brings together an international team of experts and has the potential to create positive impacts for the EHE community in Canada, and around the world. Read more here.
Rhabdo Data Analysis – A recently formed Rhabdomyosarcoma coalition of four foundations, Summer’s Way, Friends of TJ, Sebastian Strong and Maddie’s Promise have joined forces to advance Rhabdo data analysis. These foundations are jointly supporting the work of the Children’s Oncology Group Soft Tissue Sarcoma Committee through funding of a Master Statistician. This statistician is currently working on four research projects related to rhabdomyosarcoma including (1) rhabdomyosarcoma of the head and neck, (2) rhabdomyosarcoma of the orbit, (3) identification of biomarkers in relapsed rhabdomyosarcoma patients and (4) impact of race and ethnicity in rhabdomyosarcoma outcomes. Over 2,000 specimens will be entered into a database for analysis, with a potential to provide a targeted approach towards treatment and improve the outcomes of children with rhabdomyosarcoma.